329 related articles for article (PubMed ID: 31696413)
1. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
3. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
[TBL] [Abstract][Full Text] [Related]
4. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
7. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells.
Seddon A; Hock B; Miller A; Frei L; Pearson J; McKenzie J; Simcock J; Currie M
J Dermatol Sci; 2016 Aug; 83(2):124-30. PubMed ID: 27160951
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive role of CD11b
Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
[TBL] [Abstract][Full Text] [Related]
10. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
Front Immunol; 2021; 12():740890. PubMed ID: 34712230
[TBL] [Abstract][Full Text] [Related]
11. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
12. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
14. Various skin manifestations of mycosis fungoides: histopathological features and prognosis.
Koga M; Imafuku S; Nakayama J
Fukuoka Igaku Zasshi; 2011 Jul; 102(7):229-36. PubMed ID: 21879593
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
Li J; Srivastava RM; Ettyreddy A; Ferris RL
J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
[TBL] [Abstract][Full Text] [Related]
16. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.
Pileri A; Agostinelli C; Sessa M; Quaglino P; Santucci M; Tomasini C; Grandi V; Fava P; Astrua C; Righi S; Patrizi A; Pileri SA; Pimpinelli N
Virchows Arch; 2017 May; 470(5):575-582. PubMed ID: 28321511
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
18. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
Du J; Sun X; Song Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
[TBL] [Abstract][Full Text] [Related]
19. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
20. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
